HC Wainwright Has Optimistic Outlook of ATRA Q3 Earnings

Atara Biotherapeutics, Inc. (NASDAQ:ATRAFree Report) – HC Wainwright increased their Q3 2025 earnings estimates for shares of Atara Biotherapeutics in a report released on Tuesday, January 28th. HC Wainwright analyst R. Burns now anticipates that the biotechnology company will post earnings of $3.57 per share for the quarter, up from their previous estimate of $3.35. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Atara Biotherapeutics’ current full-year earnings is ($9.86) per share.

Atara Biotherapeutics (NASDAQ:ATRAGet Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same period in the prior year, the firm earned ($16.50) EPS.

Other research analysts have also issued reports about the stock. RODMAN&RENSHAW lowered shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. Rodman & Renshaw initiated coverage on shares of Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 price target on the stock. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Finally, Canaccord Genuity Group cut their target price on Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday, January 17th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Atara Biotherapeutics currently has an average rating of “Moderate Buy” and an average target price of $17.75.

Check Out Our Latest Stock Analysis on ATRA

Atara Biotherapeutics Trading Down 3.2 %

Shares of NASDAQ:ATRA opened at $8.09 on Wednesday. Atara Biotherapeutics has a 12-month low of $5.40 and a 12-month high of $39.50. The stock’s 50-day moving average price is $11.78 and its two-hundred day moving average price is $9.93. The firm has a market cap of $46.60 million, a price-to-earnings ratio of -0.31 and a beta of 0.51.

Institutional Investors Weigh In On Atara Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of ATRA. Geode Capital Management LLC increased its stake in Atara Biotherapeutics by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after buying an additional 4,043 shares during the period. State Street Corp grew its stake in shares of Atara Biotherapeutics by 52.3% during the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 7,680 shares in the last quarter. FMR LLC increased its position in shares of Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 7,381 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Atara Biotherapeutics in the second quarter worth about $79,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Atara Biotherapeutics in the second quarter valued at about $53,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

(Get Free Report)

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.

See Also

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.